The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
|Videos|November 29, 2017
Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer
Author(s)Paul Sabbatini, MD
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.
Advertisement
Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.
Dose-dense therapy or every-3-week therapy allows for many additional combinations in the primary setting, explains Sabbatini. Adding PARP inhibitors, maintenance therapy, anti-vascular agents, or other novel compounds are currently being investigated.
According to Sabbatini, it would be difficult to incorporate those into an IP with cisplatin.
Advertisement
Related to this article
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Long-term data from the L-MOCA trial showed encouraging OS outcomes with olaparib maintenance in Asian patients with platinum-sensitive, relapsed ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
5